First, it offers a rationale for the combinatorial use of BTK inhibitors and ferroptosis inducers in patients with relapsed or refractory DLBCL, particularly those with NF-κB–addicted ABC subtypes. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.